中低收入国家HPV疾病与疫苗接种规划现状:专刊导言
性传播人乳头瘤病毒(HPV)感染在男女中均极常见,多数可自然清除,但部分可进展为宫颈癌及其他癌症。尽管已有预防性疫苗和成熟的筛查治疗实践,全球HPV相关疾病负担仍高,中低收入国家尤甚。本文概述全球宫颈癌发病与死亡流行病学、全球可用HPV疫苗及中低收入国家疫苗引入现状,指出近年HPV疫苗接种覆盖率下降,强调需推进新疫苗引入并强化现有规划以实现消除宫颈癌目标。
要点
- 全球宫颈癌疾病负担仍高,非洲和亚洲负担最重。
- WHO推荐将预防性疫苗与宫颈癌筛查和治疗相结合的3重策略以消除宫颈癌。
- 近年HPV疫苗接种覆盖率下降,需推进新疫苗引入并强化现有规划。
核心结论
- 尽管有预防性疫苗和成熟的筛查治疗实践,全球HPV相关疾病负担仍高,中低收入国家尤为突出。
- 近年HPV疫苗接种覆盖率下降,需强调新疫苗引入和现有疫苗规划强化,以实现消除宫颈癌作为公共卫生问题的目标。
- 近期疫苗供应增加和单剂次有效性证据为通过疫苗接种联合筛查和治疗消除宫颈癌铺平道路。
研究设计与样本
- 本文为专刊导言,概述全球宫颈癌发病与死亡流行病学、全球可用HPV疫苗及中低收入国家疫苗引入现状。
主要发现
- 宫颈癌疾病发病与死亡负担在非洲和亚洲最高。
- 近年HPV疫苗接种覆盖率下降。
- 据估计,到2050年宫颈癌预防工作每投入1美元将回报3.20美元。
关键数值与推荐
- WHO推荐采用预防性疫苗联合宫颈癌筛查和治疗的3重策略以消除宫颈癌作为公共卫生问题。
- 据估计,到2050年宫颈癌预防工作每投入1美元将回报3.20美元。
临床怎么用
- 成功取决于战略性疫苗递送以及促进政治支持和与民间社会组织及教育部门利益相关方合作的协作。
- 通过疫苗接种联合筛查和治疗消除宫颈癌的路径得到近期疫苗供应增加和单剂次有效性证据的支持。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sexually transmitted human papillomavirus (HPV) infections are extremely common in both men and women and while most will clear naturally, some may progress to cervical cancer and other cancers. Despite the availability of prophylactic vaccines and well-established screening and treatment practices, the global burden of HPV-related disease remains high, particularly in low-and-middle-income countries (LMICs). We outline the current global epidemiology of cervical cancer disease incidence and mortality, with the highest burden in Africa and Asia. As part of a strategy to eliminate cervical cancer as a public health problem, the WHO recommends a 3-fold approach combining the use of prophylactic vaccines with cervical cancer screening and treatment. This overview focuses on the globally available HPV vaccines and current status of vaccine introduction in LMICs. We describe decreased HPV vaccination coverage in recent years and highlight the need for emphasis on new vaccine introductions and existing vaccine programme strengthening in order to reach goals for the elimination of cervical cancer as a public health problem. It is estimated that US$3.20 will be returned on each dollar invested in cervical cancer prevention efforts through 2050 [1]. Success for these initiatives centers on strategic vaccine delivery and collaborations that foster political support and engagement with civil society organisations and educational sector stakeholders. Recent increases in vaccine supply and single-dose efficacy evidence pave the way for cervical cancer elimination through vaccination coupled with screening and treatment. Subsequent manuscripts in this supplement will outline case studies and lessons from two symposia held in Africa and South Asia by the Coalition to Strengthen the HPV Immunization Community in 2022 including evidence for a one-dose strategy, the challenges of maintaining vaccine programmes during the COVID-19 pandemic, and progress in cervical cancer screening programmes.
引用
- Borda H, Bloem P, Akaba H, et al. Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue. Vaccine. 2024. PMID: 39521565. doi:10.1016/j.vaccine.2023.10.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。